SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · IEX Real-Time Price · USD
0.734
+0.026 (3.67%)
At close: Mar 28, 2024, 4:00 PM
0.760
+0.026 (3.53%)
After-hours: Mar 28, 2024, 7:59 PM EDT
Company Description
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers inflammatory response to fend off infections and repair damaged tissue in the body.
It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.
SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.
SeaStar Medical Holding Corporation
Country | United States |
Founded | 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Eric Schlorff |
Contact Details
Address: 3513 Brighton Blvd, Suite 410 Denver, Colorado 80216 United States | |
Phone | 844-427-8100 |
Website | seastarmedical.com |
Stock Details
Ticker Symbol | ICU |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001831868 |
ISIN Number | US81256L1044 |
Employer ID | 85-3681132 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Eric Schlorff | Chief Executive Officer, President and Executive Director |
Dr. H. David Humes M.D. | Co-Founder and Managing Director |
Colonel Kevin Chung FACP, M.D. | Chief Medical Officer |
David A. Green CPA, M.B.A. | Chief Financial Officer |
Tom Mullen | Vice President of Operations and Product Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 8-K/A | [Amend] Current report |
Mar 27, 2024 | 8-K | Current Report |
Mar 27, 2024 | 8-K | Current Report |
Mar 8, 2024 | 8-K | Current Report |
Mar 5, 2024 | 424B3 | Prospectus |
Mar 5, 2024 | 424B3 | Prospectus |
Mar 5, 2024 | 424B3 | Prospectus |
Mar 5, 2024 | 424B3 | Prospectus |
Mar 5, 2024 | 424B3 | Prospectus |
Mar 5, 2024 | 424B3 | Prospectus |